ProCE Banner Activity

CDK4/6 and PI3K Inhibitors for HR+/HER2- Breast Cancer in the Clinic Today: Thoughts From the Experts

Clinical Thought

Faculty review recent clinical trial data and provide their insights on the use of CDK4/6 inhibitors and PI3K inhibitors for HR+/HER2- breast cancer.

Resources for your patients: https://www.smartpatients.com/resources/cco-breast-cancer

Released: March 23, 2021

Expiration: March 22, 2022

Share

Faculty

Matthew P. Goetz

Matthew P. Goetz, MD

Professor of Oncology and Pharmacology
Director, Mayo Breast Cancer SPORE
Co-PI, Womens Cancer Program
Department of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Sara Hurvitz

Sara Hurvitz, MD

Assistant Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Internal Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Supporters

Supported by an educational grant from

Lilly

Partners

Smart Patients

ProCE Banner

Faculty Disclosure

Primary Author

Matthew P. Goetz, MD

Professor of Oncology and Pharmacology
Director, Mayo Breast Cancer SPORE
Co-PI, Womens Cancer Program
Department of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Matthew P. Goetz, MD, has disclosed that he has received consulting fees paid to his institution from Biotheranostics, Biovica, Context, Eagle Pharmaceuticals, Lilly, Novartis, Pfizer, and Sermonix and has received funds for research support paid to his institution from Lilly, Pfizer, and Sermonix.

Sara Hurvitz, MD

Assistant Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Internal Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Sara Hurvitz, MD, FACP, has disclosed that she has received funds for research support from Ambrx, Amgen, Arvinas, AstraZeneca, Bayer, Daiichi Sankyo, Dignitana, Genentech/Roche, Gilead Sciences, GlaxoSmithKline, Immunomedics, Lilly, MacroGenics, Novartis, OBI, Pfizer, Phoenix Molecular Designs, Pieris, Puma, Radius, Sanofi, Seattle Genetics, and Zymeworks.